Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery (Q37847150)

24 August 2017

1 reference

title

Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery (English)

1 reference

24 August 2017

1 reference

1 reference

Sorrel E Wolowacz

1

1 reference

24 August 2017

1 February 2011

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

1

1 reference

24 August 2017

9-25

1 reference

Antithrombotic therapy practices in US hospitals in an era of practice guidelines

24 August 2017

1 reference

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 January 2018

1 reference

Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review

21 January 2018

1 reference

Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry

21 January 2018

1 reference

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials

21 January 2018

1 reference

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

21 January 2018

1 reference

Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin

21 January 2018

1 reference

Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin

21 January 2018

1 reference

Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban

21 January 2018

1 reference

Dabigatran versus enoxaparin after total hip replacement

21 January 2018

1 reference

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery

21 January 2018

1 reference

Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement

21 January 2018

1 reference

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting

21 January 2018

1 reference

Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty

21 January 2018

1 reference

Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the U

21 January 2018

1 reference

How patients with atrial fibrillation value different health outcomes: a standard gamble study

21 January 2018

1 reference

The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.

21 January 2018

1 reference

Use of indirect and mixed treatment comparisons for technology assessment

21 January 2018

1 reference

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

21 January 2018

1 reference

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).

21 January 2018

1 reference

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERP.10.89

1 reference

24 August 2017

1 reference

PubMed ID

21351853